<DOC>
	<DOCNO>NCT00914368</DOCNO>
	<brief_summary>The primary objective study establish cut level platelet inhibition separate patient without previous stent occlusion acute clinical onset aspirin clopidogrel treatment within 6 month coronary stenting coronary artery disease .</brief_summary>
	<brief_title>Tailoring Of Platelet Inhibition Avoid Stent Thrombosis</brief_title>
	<detailed_description>To establish cut level platelet inhibition use ADP-induced P2Y12-receptor mediate platelet aggregation use Accumetrics VerifyNow P2Y12 assay ( PRU ) Vasodilator-stimulated phosphoprotein ( VASP , PRI % ) patient experience stent occlusion acute clinical onset and/or myocardial infarction within 6 month coronary stenting coronary artery disease .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Provide sign write informed consent . Male female patient 18 year old . Previous PCI coronary stenting coronary artery disease Previous ( coronary stenting ) current dual antiplatelet treatment ( aspirin 75 mg daily ( o.d ) clopidogrel 75 mg o.d ) . All patient need treatment aspirin 75 mg daily least seven day prior enrollment . Experienced one follow alternative : Stent thrombosis within 6 month PCI dual antiplatelet treatment ; OR Experienced MI within 6 month coronary stenting dual antiplatelet treatment ; OR No experience stent thrombosis MI least 6 month visit 1 ( match control ) General exclusion criterion : 1 . Women know pregnant , give birth within past 90 day , breastfeed . 2 . Any condition laboratory finding opinion Investigator make patient unsuitable inclusion 3 . Enrolled either another investigational drug study another investigational study approve drug within 30 day prior Visit 1 current study . 4 . Known allergy intolerance aspirin and/or thienopyridines ( clopidogrel ticlopidine ) . 5 . Significant active neuropsychiatric disease , alcohol abuse drug abuse , investigator 's opinion . 6 . UCR Accumetrics employee investigator site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . Cardiovascular 7 . Subjects unstable coronary artery disease , define new , increased , rest angina screen . 8 . Subjects significant hypertension ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mmHg ) time screen . Bleeding Risk 9 . Any known contraindication treatment anticoagulant antiplatelet agent . 10 . Prior history presence significant bleeding disorder ( example , hematemesis , melena , severe recurrent epistaxis , hemoptysis , hematuria , intraocular bleeding ) 11 . Prior history clinical suspicion cerebral vascular malformation 12 . Prior history abnormal bleeding tendency ( i.e . prolonged bleeding dental extraction , tonsillectomy , previous surgical procedure ) . 13 . Personal family history coagulation bleed disorder . 14 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) thrombocytosis ( platelet count &gt; 500,000/mm3 ) . 15 . History major surgery , severe trauma , organ biopsy within 3 month prior enrollment . 16 . Any planned surgical procedure within 20 day follow inclusion . 17 . The use ( plan use ) antiplatelet agent ( besides aspirin clopidogrel ) , anticoagulant fibrinolytic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Disease</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Syndrome</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>